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Approximately 20% of breast cancers exhibit ampli-
ﬁ cation of the HER2 proto-oncogene on chromosome 17, 
and without adequate treatment these tumors tend to 
have an aggressive natural history [1,2]. Large random-
ized adjuvant trials show signiﬁ cant reductions in distant 
recurrence and death for early-stage women treated with 
adjuvant trastuzumab [3-6]. Recent long-term follow-up 
of the joint analysis of the NCCTG 9831 and B-31 studies 
show improved disease-free survival (DFS) and overall 
survival (OS) for women who received adjuvant trastu-
zumab [3], with a trend toward greater improvement in 
DFS with concurrent use of trastuzumab and chemo-
therapy in comparison to sequential use of trastuzumab 
after chemotherapy in NCCTG 9831 [7]. Th ese ground-
breaking results were tempered by a relatively high rate 
of clinically signiﬁ cant congestive heart failure (2.5%) 
with adjuvant regimens containing both an anthracycline 
and traztuzumab [3,4]. It is with great interest, therefore, 
that Dr Slamon and colleagues [5] published the long-
awaited results of the pivotal Breast Cancer International 
Research Group 006 (BCIRG-006) trial, containing a 
non-anthracycline-containing anti-Her2 adjuvant chemo-
therapy regimen in one arm, in the New England Journal 
of Medicine in October 2011.
BCIRG-006 included over 3,000 women with either 
high-risk node-negative or node-positive early-stage 
HER2-positive breast cancer. HER2 status was centrally 
determined. Women were randomized to one of three 
regimens: (1)  docetaxel plus carboplatin for six cycles 
concurrently with trastuzumab followed by an additional 
34  weeks of trastuzumab (TCH); (2)  doxorubicin and 
cyclophosphamide for four cycles followed by docetaxel 
for four cycles with trastuzumab starting with docetaxel 
and continuing for one year (AC-TH); or (3) a regimen of 
doxorubicin and cyclophosphamide for four cycles 
followed by docetaxel for four cycles (AC-T). At median 
follow-up of 65 months, the two trastuzumab-containing 
arms (TCH and AC-TH) showed statistically signiﬁ cant 
improvements in both DFS (AC-TH 84%, TCH 81% 
versus AC-T 75%, P < 0.001) and OS (AC-TH 92%, TCH 
91% versus AC-T 87%, P  <  0.001) in comparison to the 
non-trastuzumab-containing arm (AC-T). Th e rates of 
DFS and OS were not statistically diﬀ erent for the two 
trastuzumab-containing arms, but the study was not 
powered to detect equivalence between these two regi-
mens. Th e beneﬁ t of both TCH and AC-TH over AC-T 
was conﬁ rmed in patients with lymph node-negative 
disease, patients with lymph node-positive disease, and 
patients with four or more lymph node-positive disease.
An analysis of topoisomerase II (TOP2A) gene ampli ﬁ -
cation and DFS was also performed. In the 35% of women 
with HER2-positive breast cancer that co-ampliﬁ ed 
HER2 and TOP2A on chromosome 17, there appeared to 
be no incremental beneﬁ t to traztuzumab in the TCH 
and AC-TH arms over AC-T.
A ﬁ ve-fold higher rate of congestive heart failure was 
seen with AC-T plus trastuzumab than with TCH (2.0% 
and 0.4%, respectively, P  <  0.001), and more acute 
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leukemias were seen in the two anthracycline-containing 
arms than in the TCH arm. Vomiting, arthralgias, 
myalgias, neuropathy, neutropenia and leukopenia were 
signiﬁ cantly lower in the TCH group; anemia and 
thrombocytopenia were lower in the AC-TH group, and 
there was no signiﬁ cant diﬀ erence in febrile neutropenia 
between the arms.
Th ere were fewer distant recurrences of breast cancer 
in the AC-TH arm than the TCH arm (124 versus 144). 
Th ere were more congestive heart failure events in the 
AC-TH arm (21 versus 4), and one acute leukemia in 
both arms, for a total event rate of 146 for AC-TH versus 
149 for TCH.
In summary, there are good reasons to administer 
either TCH or an anthracycline-containing regimen (AC-
TH or AC-paclitaxel/traztuzumab) in the adjuvant 
setting after local therapy for HER2-positive early stage 
breast cancer. It is gratifying that both regimens have a 
5 year OS rate above 90%, and that both regimens have a 
5 year DFS rate of at least 73% in women with poor risk 
disease with four or more positive lymph nodes. Th e 
natural history of this aggressive subtype of breast cancer 
has indeed been changed. Which regimen chosen will 
likely depend on the comorbidity of the individual 
patient, and the desire to avoid cardiotoxicity.
Looking forward, no clear marker has materialized as a 
reliable predictor of traztuzumab resistance in the adju-
vant setting. Newer agents are under active investigation 
and may improve outcomes for early-stage patients in 
combination with traztuzumab-based adjuvant therapy. 
Th ere also remains a lack of clarity regarding traztuzumab 
beneﬁ t for HER2-negative and/or HER2-low patients. 
Finally, traztuzumab has yielded major advances in the 
treatment of an aggressive breast cancer phenotype, but 
oncologists remain divided regarding the relative risk- 
beneﬁ t ratio of anthracyclines within traztuzumab-
containing adjuvant regimens [8,9].
Mechanisms of resistance to trastuzumab are complex 
and likely involve, in part, alternative signaling pathways 
and/or constitutive activation of the phosphoinositide 
3-kinase/Akt signaling pathway. Newer agents show 
promise in resistant patients with advanced disease. 
Pertuzumab, a monoclonal antibody that binds to HER2 
and inhibits heterodimeriza tion with other receptors of 
the Her superfamily, has shown progression-free survival 
beneﬁ t in a phase III study in advanced disease [10] and 
is being studied in combination with trastuzumab with 
either anthracyline or non-anthracycline-based 
chemotherapy in the ongoing adjuvant APHINITY trial 
(NCT01358877). Trastuzumab-DM1, a con jugate of 
trastuzumab and a potent microtubule polymerization 
inhibitor (a derivate of maytansine) has shown a 
progression-free survival advantage in a phase II study of 
advanced disease [11]. Persistent HER3 signaling is 
another mechanism of therapeutic resistance, and anti-
HER3 antibodies are in pre-clinical development. 
Combination studies of HER2-targeted agents with more 
potent, irreversible inhibitors of the epidermal growth 
factor receptor-HER2 family, such as Neratinib, are 
ongoing (NCT01423123). Retro spective analyses show-
ing trastuzumab beneﬁ t in HER2-negative patients [12] 
and a recent revised analysis of the N9831 trial showed 
similar DFS improvements with trastu zumab therapy in 
patients HER2-positive by US Food and Drug Adminis-
tration criteria, but negative by the revised American 
Society of Clinical Oncology (ASCO)/College of American 
Pathologists (CAP) criteria [13], making the ongoing 
pros pective NSABP trial (NCT01275677) looking at 
trastuzumab in HER2-low patients a priority to deﬁ ne 
trastuzumab beneﬁ t for those patients considered HER2-
low or -negative.
Despite improvements in treatment of advanced 
HER2-positive disease, many patients ultimately die due 
to progression of disease at visceral sites, so it is critical 
to increase success rates in the adjuvant setting.
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